Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Piper Sandler

Equities research analysts at Piper Sandler began coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research note issued on Tuesday. The brokerage set an “overweight” rating and a $24.00 price target on the stock. Piper Sandler’s price objective indicates a potential upside of 91.69% from the company’s previous close.

GENB has been the topic of a number of other reports. Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Cantor Fitzgerald started coverage on Generate Biomedicines in a report on Tuesday. They issued an “overweight” rating on the stock. Guggenheim initiated coverage on Generate Biomedicines in a research note on Tuesday. They issued a “buy” rating and a $30.00 price target on the stock. Morgan Stanley began coverage on Generate Biomedicines in a report on Tuesday. They set an “overweight” rating and a $20.00 price target for the company. Finally, The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $26.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $25.00.

Generate Biomedicines Price Performance

Shares of Generate Biomedicines stock opened at $12.52 on Tuesday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.